Wednesday, July 8, 2026

Patent intelligence · US

US 8716321

Methods for dosing an orally active 1,2,4-oxadiazole

granted A61KA61K31/4245A61K9/0053A61K9/145
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 8
Applicant portfolio 149
Patent details — US 8716321
Jurisdiction
US
Status
granted
Grant date
May 6, 2014
Expiration
May 1, 2034
Claims
31
CPC classes
A61K, A61K31/4245, A61K9/0053, A61K9/145
View on Google Patents ↗

Quick answer

US 8716321 (Methods for dosing an orally active 1,2,4-oxadiazole) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted May 6, 2014. Expires May 1, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
31
CPC classes
A61K, A61K31/4245, A61K9/0053, A61K9/145, A61P, A61P1/16

More from PTC THERAPEUTICS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12398140

    Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia

    PTC THERAPEUTICS, INC. · Expires Aug 21, 2045

    granted
  2. US 12384789

    Compounds for treating Huntington's disease

    PTC THERAPEUTICS, INC. · Expires Aug 7, 2045

    granted
  3. US 12384797

    Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia

    PTC THERAPEUTICS, INC. · Expires Aug 7, 2045

    granted
  4. US 12281083

    2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof

    PTC THERAPEUTICS, INC. · Expires Apr 17, 2045

    granted
  5. US 12139499

    Heteroaryl compounds for treating Huntington's disease

    PTC THERAPEUTICS, INC. · Expires Nov 7, 2044

    granted
  6. US 12103926

    Compounds for treating huntington's disease

    PTC THERAPEUTICS, INC. · Expires Sep 26, 2044

    granted
  7. US 12023335

    Method for treating pancreatic cancer

    PTC THERAPEUTICS, INC. · Expires Jun 27, 2044

    granted
  8. US 11938101

    Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

    PTC THERAPEUTICS, INC. · Expires Mar 21, 2044

    granted

Frequently asked questions

What is US patent 8716321?

US 8716321 (Methods for dosing an orally active 1,2,4-oxadiazole) is held by PTC THERAPEUTICS, INC.. Status: granted. Granted May 6, 2014. Expires May 1, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8716321?

PTC THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 149 pharmaceutical patents for this assignee.

When does US 8716321 expire?

Our index shows an expiration date of May 1, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.